Disposition of 3500 shares by Todd Harris of Tyra Biosciences at 24.0 subject to Rule 16b-3
TYRA Stock | USD 16.00 0.28 1.78% |
About 65% of all Tyra Biosciences' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Tyra Biosciences suggests that some traders are interested. The current market sentiment, together with Tyra Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Tyra Biosciences stock news signals to limit their universe of possible portfolio assets.
Tyra |
Filed transaction by Tyra Biosciences Director, Officer: President And Ceo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at thelincolnianonline.com
Tyra Biosciences Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Tyra Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Tyra Biosciences Fundamental Analysis
We analyze Tyra Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tyra Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tyra Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Tyra Biosciences is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Tyra Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tyra Biosciences stock to make a market-neutral strategy. Peer analysis of Tyra Biosciences could also be used in its relative valuation, which is a method of valuing Tyra Biosciences by comparing valuation metrics with similar companies.
Peers
Tyra Biosciences Related Equities
IPSC | Century Therapeutics | 20.74 | ||||
RAPT | RAPT Therapeutics | 9.82 | ||||
CCCC | C4 Therapeutics | 8.59 | ||||
GLUE | Monte Rosa | 5.93 | ||||
ERAS | Erasca | 5.04 | ||||
MLYS | Mineralys Therapeutics, | 4.71 | ||||
MOLN | Molecular Partners | 3.19 | ||||
CGEM | Cullinan Oncology | 2.51 | ||||
XLO | Xilio Development | 2.02 | ||||
STOK | Stoke Therapeutics | 1.19 | ||||
PMVP | Pmv Pharmaceuticals | 0.63 | ||||
HOWL | Werewolf Therapeutics | 0.51 | ||||
EWTX | Edgewise Therapeutics | 0.37 | ||||
CNTB | Connect Biopharma | 0.97 | ||||
IKNA | Ikena Oncology | 1.17 | ||||
DSGN | Design Therapeutics | 2.93 | ||||
PHVS | Pharvaris | 7.49 |
Complementary Tools for Tyra Stock analysis
When running Tyra Biosciences' price analysis, check to measure Tyra Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tyra Biosciences is operating at the current time. Most of Tyra Biosciences' value examination focuses on studying past and present price action to predict the probability of Tyra Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tyra Biosciences' price. Additionally, you may evaluate how the addition of Tyra Biosciences to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |